“Eligibility Is Not Enough”: Rule 9(b) Requires Indicia of Actual Government-Reimbursed Claims in Inducement FCA Pleading

1. Introduction

This First Circuit decision addresses what a relator must plead to survive a motion to dismiss in an inducement-based False Claims Act (FCA) case. Relators Reynaldo Solano and Neals Maxilin alleged that Barton Associates, Inc. orchestrated a scheme: Barton purportedly recruited “clients” to solicit Medicare-eligible patients, routed those patients to Barton-affiliated physicians to “rubberstamp” prescriptions, charged the clients a per-prescription “assessment fee,” and the clients then billed Medicare or other government programs.

The core issues were: (1) whether the complaint satisfied Federal Rule of Civil Procedure 9(b)’s heightened fraud pleading standard under the First Circuit’s “more flexible” approach for inducement theories; and (2) whether the district court abused its discretion in denying reconsideration and, alternatively, leave to amend after judgment entered.

2. Summary of the Opinion

The First Circuit affirmed across the board. It held that the complaint failed Rule 9(b) even under the inducement framework because it did not allege “reliable indicia” supporting a strong inference that false claims were actually submitted to government payors. Critically, the complaint described patients as “Medicare eligible” but did not plead facts showing any particular patient was enrolled in Medicare (or another government program) such that claims were actually presented for government payment.

The court also upheld the denial of reconsideration and amendment. A contingent, “in the event of dismissal” request is not a proper pre-judgment motion to amend, and a post-judgment request to amend cannot be granted unless the judgment is first set aside. The relators further failed to supply a proposed amended complaint or specific proffer showing how they would cure deficiencies.

3. Analysis

3.1 Precedents Cited (and How They Shaped the Holding)

• United States ex rel. Duxbury v. Ortho Biotech Prods., L.P.
  Duxbury is the First Circuit’s key inducement-pleading case. It recognizes that, in inducement theories, relators need not always identify each claim number, but must plead “particular details of a scheme” plus “reliable indicia” that claims were actually submitted. Here, the court used Duxbury both as the governing standard and as a contrast: Duxbury included provider-specific details and concrete claim-related information (dates/amounts tied to Medicare billing), whereas Solano/Maxilin did not.
• United States ex rel. Grubbs v. Kanneganti
  Quoted through Duxbury for the “scheme + reliable indicia” formulation. It provided the doctrinal source for allowing inducement cases to proceed without pleading every claim—provided the complaint supplies robust claim-submission indicia.
• United States ex rel. Ge v. Takeda Pharm. Co.
  Ge supplied the “who, what, when, where, and how” articulation and the rule that misconduct unlinked to claim submission is insufficient. It also supported the procedural holding that post-judgment amendment requires the judgment to be set aside first.
• Lawton ex rel. United States v. Takeda Pharm. Co.
  Cited for the proposition that Rule 9(b) demands particularity both as to the “circumstances of the alleged fraud” and “the claims themselves.” This reinforced that pleading a “scheme” alone does not satisfy Rule 9(b) without meaningful claim-presentment content.
• Hagerty ex rel. United States v. Cyberonics, Inc.
  Hagerty contributed two pivotal ideas used to affirm dismissal: (1) even under a “somewhat more flexible” inducement standard, the complaint must “strengthen the inference of fraud beyond possibility”; and (2) insinuations are not enough where the pleading fails to allege that any particular patient was “actually covered” by a government program. Solano/Maxilin’s “eligible” allegations fell into that gap.
• United States ex rel. Kelly v. Novartis Pharms. Corp.
  Kelly served as the closest analogue and the court’s main comparative tool. Like Kelly, this complaint alleged suspicious conduct and incentives but lacked reliable indicia that the conduct resulted in claims to federal payors. The court treated the relators’ theory here—at most—as “speculation,” mirroring Kelly’s reasoning.
• United States ex rel. Garcia v. Novartis AG
  Cited for factual background to Kelly, underscoring that even fairly detailed allegations of improper inducements may still fail absent clear linkage to federal reimbursement.
• Fisher v. Kadant, Inc.
  Controlled the amendment point: a “passing request for contingent leave” embedded in opposition to dismissal is not a proper Rule 15 motion.
• Aponte-Torres v. Univ. of P.R. and Silverstrand Invs. v. AMAG Pharms., Inc.
  These cases supported denying leave to amend where the movant supplies no proposed amendment or concrete explanation of how defects would be cured—especially salient in fraud cases with known pleading deficiencies.
• Acosta-Mestre v. Hilton Int'l of P.R., Inc.
  Reinforced that appellate courts may affirm denial of leave to amend if any adequate reason appears in the record, even if the district court’s explanation is limited.
• Ruiz Rivera v. Pfizer Pharms., LLC
  Supplied the deferential standard for reviewing Rule 59(e) denials and the breadth of district-court discretion.
• ACA Fin. Guar. Corp. v. Advest, Inc., Palmer v. Champion Mortg., and Marie v. Allied Home Mortg. Corp.
  These cases frame reconsideration as an “extraordinary remedy” requiring manifest legal error or newly discovered evidence, and they reject using Rule 59(e) simply to reargue previously rejected theories—precisely what the First Circuit said occurred here.
• Davila-Alvarez v. Escuela de Medicina Universidad Cent. del Caribe
  Used to rebut the relators’ characterization of precedent; it involved Rule 60(b) and did not support their asserted Rule 59(e) requirement that district courts must always articulate a rationale.

3.2 Legal Reasoning

A. Rule 9(b) in Inducement-Based FCA Theories: “Scheme” Must Still Connect to Claim Submission

The court accepted that this was an inducement theory and that United States ex rel. Duxbury v. Ortho Biotech Prods., L.P. supplies a more accommodating way to plead fraud without identifying each false claim. But the accommodation is limited: the complaint must still provide “reliable indicia” supporting a strong inference that claims were actually submitted to government programs.

Applied to the pleaded facts, the court treated the relators’ allegations as largely schematic: Barton recruited clients, clients solicited patients, Barton physicians approved requests at a very high rate, and clients allegedly obtained large volumes of prescriptions or performed many tests. The court found this did not supply the missing link—factual content showing actual submission of claims to Medicare (or other government payors) for the challenged items/services.

B. The Opinion’s Central Pleading Point: “Medicare Eligible” ≠ Medicare-Enrolled (and the Gap Is Fatal)

A defining feature of the opinion is its insistence that describing patients as “Medicare eligible” does not plausibly allege that claims were submitted to Medicare. Without facts indicating that particular patients were actually covered/enrolled (or that particular claims were actually presented to a government program), the complaint does not cross the Rule 9(b) threshold from possibility to strong inference.

C. Post-Judgment Procedure: Amendment and Reconsideration

• Amendment: The court emphasized timing and form. A contingent oral request at a dismissal hearing is not a proper pre-judgment motion to amend (per Fisher v. Kadant, Inc.). After dismissal with prejudice and entry of judgment, amendment cannot be granted unless the judgment is vacated first (per United States ex rel. Ge v. Takeda Pharm. Co.).
• No proffer: The relators did not provide a proposed amended complaint or explain, concretely, what facts they would add—an independent basis to deny leave (per Aponte-Torres v. Univ. of P.R. and Silverstrand Invs. v. AMAG Pharms., Inc.).
• Reconsideration: The court treated the Rule 59(e) filing as reargument, not correction of manifest error or presentation of new evidence, making denial well within discretion (per Palmer v. Champion Mortg. and related cases).

3.3 Impact

• Pleading discipline in FCA inducement cases: The decision reaffirms that the “flexible” Duxbury route is not a shortcut around presentment. Relators must plead facts that make actual government reimbursement more than conjecture—especially where the defendant is one step removed from billing.
• Coverage specificity matters: The “eligible vs. enrolled/covered” distinction will likely be cited by defendants to attack complaints that rely on demographic or marketing categories (e.g., “Medicare-aged,” “Medicare-eligible”) rather than alleging coverage and billing.
• Post-judgment amendment hurdles: The opinion is a procedural warning: relators should file a concrete motion to amend (with a draft) before judgment, not rely on conditional requests, and not expect Rule 59(e) to serve as an amendment vehicle.

4. Complex Concepts Simplified

• Qui tam (FCA): A whistleblower (“relator”) sues on behalf of the government, alleging fraud against federal funds; the government may intervene or decline.
• Inducement FCA theory: The defendant may be liable not only for submitting claims itself, but for causing others to submit false claims. Even then, the case must plausibly connect the scheme to actual claims for government payment.
• Rule 9(b) “particularity”: Fraud must be pled with specifics—typically the “who, what, when, where, and how.” In FCA cases, this includes specifics indicating that false claims were actually presented to a government payor.
• Rule 59(e) reconsideration: A narrow mechanism to correct manifest legal error or consider newly discovered evidence—not a second chance to argue the same points.
• Post-judgment amendment: Once final judgment enters, a court generally must vacate/set aside the judgment before allowing an amended complaint.

5. Conclusion

USA, ex rel. Solano v. Barton Associates, Inc. reinforces a concrete pleading requirement in inducement-based FCA litigation: alleging a persuasive scheme and high-volume activity is not enough without “reliable indicia” that false claims were actually submitted to government programs. The opinion crystallizes a practical rule for Rule 9(b): describing patients as “Medicare eligible” does not bridge the gap to Medicare presentment. Procedurally, it also underscores that post-judgment amendment and reconsideration are exceptional—and require timely, properly supported motions rather than contingent requests or conclusory promises to cure defects.